Dr. Leon A. Palandjian

• 
  www.flagshipventures.com/lpalandjian.html - [Cached Version]
  Published on: 10/29/2003    Last Visited: 10/29/2003  

  Leon A. Palandjian, M.D.
  ...
  Leon A. Palandjian, M.D.
  ...
  Leon Palandjian, Principal of Flagship Ventures, has served as a founding Principal for AGTC and joined the firm in early 2000 while finishing his MD degree from Harvard Medical School.While at medical school, Leon was a Cell Biology Research Fellow studying RNA splicing.He is a contributing author on four original manuscripts and a textbook chapter.From 1991-1994 Leon held the position of Management Associate in SmithKline Beecham's pharmaceutical division, gaining experience in the operational areas of manufacturing, human resources, sales, and R&D.Leon has also been active for many years as a private investor and advisor to a real estate investment fund, and was a summer associate at Bain Capital.He serves on Dana Farber Cancer Institute's Visiting Committee for Patient and Family Care Services.He earned a B.A. in Economics from Harvard College.
  
  Leon currently works closely with the following Flagship companies: Adaptive Therapeutics, Beyond Genomics, Cellular Genomics and Genomics Collaborative.

• 
  www.agtcfunds.com/leon.htm - [Cached Version]
  Published on: 11/22/2001    Last Visited: 11/22/2001  

  Leon Palandjian
  
  Doug
  
  Contact Us
  
  ...
  Leon Palandjian
  
  Leon A. Palandjian, M.D., Principal
  
  Leon Palandjian is a founding Principal of AGTC Funds and joined the firm in early 2000 while finishing his MD degree from Harvard Medical School.While at medical school, Leon was a Cell Biology Research Fellow studying RNA splicing.He is a contributing author on four original manuscripts and a textbook chapter.From 1991-1994 he held the position of Management Associate in SmithKline Beecham's pharmaceutical division, gaining experience in the operational areas of manufacturing, human resources, sales, and R&D.He has also been active for many years as a private investor and advisor to a real estate investment fund, and was a summer associate at Bain Capital.Leon serves as a board observer at Beyond Genomics, Cellular Genomics, engeneOS, and Genomics Collaborative.He is on Dana Farber Cancer Institute's Visiting Committee for Patient and Family Care Services.He is a Level II candidate in the CFA Program and earned a B.A. in Economics from Harvard College.
  
  [ Overview ] [ Opportunity ] [ People ] [ Contact Us ] [ News ] [ Partners ] [ Companies ] [ Presentations ]
  
  Send mail to info@agtcfunds.com with questions or comments about this web site.Last modified: October 26, 2001

• 
  AGTC Funds News - [Cached Version]
  Published on: 10/17/1999    Last Visited: 9/8/2000  

  Leon Palandjian, M.D., Principal, is a recent graduate of Harvard Medical School, and a member of the Patient Care Visiting Committee of the Dana-Farber Cancer Institute.Previously, he was a researcher at Harvard Medical School, and is the author of numerous papers on RNA splicing.From 1991-94 Dr. Palandjian was a Management Associate with SmithKline Beecham, gaining experience in manufacturing, R&D, human resources and sales.
  
  NewcoGen Group (http://www.newcogen.com/) was formed in late 1999 to focus on creating and developing new ventures in the life science and information technology fields.NewcoGen applies a systematic entrepreneurial process that is used to identify and develop companies capable of achieving leadership positions in attractive target markets.New venture concepts are either generated internally or sourced externally from a network of NewcoGen Group advisors, academics, entrepreneurs, venture capital referrals or corporate partners.Based in Cambridge, Massachusetts, NewcoGen has assembled a team of over 40 life sciences and information technology professionals among its core staff and current start-up projects.The Group has approximately $60 million in capital from institutional and corporate partners, including Elan Corporation and PE Corporation.

• 
  Beyond Genomics - [Cached Version]
  Published on: 6/29/2001    Last Visited: 10/28/2002  

  Leon Palandjian, MD, principal of AGTC Funds/Flagship Ventures said, "With this additional capital, BG will be able to apply its technologies toward a better understanding of disease etiology and potential points of pharmaceutical intervention.BG's multi-disciplinary approach provides integrated information to the pharmaceutical industry which to date has been impossible to ascertain."

• 
  BioExchange - Life Sciences and Biotechnology Resource... - [Cached Version]
  Published on: 2/13/2002    Last Visited: 2/27/2002  

  Leon Palandjian, MD, principal of AGTC Funds/Flagship Ventures said, ``With this additional capital, BG will be able to apply its technologies toward a better understanding of disease etiology and potential points of pharmaceutical intervention.BG's multi-disciplinary approach provides integrated information to the pharmaceutical industry which to date has been impossible to ascertain.''

• 
  Boston Globe Online / Business / Biotech firms nudged... - [Cached Version]
  Published on: 2/14/2002    Last Visited: 2/14/2002  

  In the last two years, about $10 billion of private money has been pumped into the biotech sector nationally, said Leon Palandjian, founding principal of AGTC Funds, a Cambridge venture capital firm specializing in the life sciences.His firm, he said, ''is sitting on a number of proposals'' from would-be biotech entrepreneurs. ''And we'll end up cofounding some of these ventures with others.''
  
  ''Start-ups don't need the marque location of Cambridge,'' Palandjian said, adding that building costs and rents are also lower in the suburbs.

• 
  GSAS Harvard Biotechnology Club - [Cached Version]
  Published on: 5/1/2002    Last Visited: 9/20/2007  

  Leon A. Palandjian, M.D.Principal of Flagship Ventures

• 
  Illinois Venture Capital Association - What's New -... - [Cached Version]
  Published on: 2/14/2002    Last Visited: 4/4/2002  

  In the last two years, about $10 billion of private money has been pumped into the biotech sector nationally, said Leon Palandjian, founding principal of AGTC Funds, a Cambridge venture capital firm specializing in the life sciences.His firm, he said, 'is sitting on a number of proposals' from would-be biotech entrepreneurs. 'And we'll end up cofounding some of these ventures with others.'
  
  'Start-ups don't need the marque location of Cambridge,' Palandjian said, adding that building costs and rents are also lower in the suburbs.

• 
  NewcoGen - [Cached Version]
  Published on: 3/5/2001    Last Visited: 11/6/2001  

  Leon Palandjian , M.D. , Principal , is a recent graduate of Harvard Medical School , and a member of the Patient Care Visiting Committee of the Dana-Farber Cancer Institute.Previously , he was a researcher at Harvard Medical School , and is the author of numerous papers on RNA splicing.From 1991 to 1994 Dr. Palandjian was a Management Associate with SmithKline Beecham , gaining experience in manufacturing , R&D , human resources and sales.
  
  NewcoGen was formed in late 1999 to focus on creating and developing new ventures in the life science and information technology fields.NewcoGen applies a systematic entrepreneurial process that is used to identify and develop companies capable of achieving leadership positions in attractive target markets.New venture concepts are either generated internally or sourced externally from a network of NewcoGen advisors , academics , entrepreneurs , venture capital referrals or corporate partners.Based in Cambridge , Massachusetts , NewcoGen has assembled a team of more than 75 life sciences and information technology professionals among its core staff and six current start-up ventures.NewcoGen has approximately $62 million in capital from institutional and corporate partners , including Elan Corporation and Applera Corporation.

• 
  NewcoGen - [Cached Version]
  Published on: 3/5/2001    Last Visited: 1/10/2002  

  Leon Palandjian, M.D., Principal, is a recent graduate of Harvard Medical School, and a member of the Patient Care Visiting Committee of the Dana-Farber Cancer Institute.Previously, he was a researcher at Harvard Medical School, and is the author of numerous papers on RNA splicing.From 1991 to 1994 Dr. Palandjian was a Management Associate with SmithKline Beecham, gaining experience in manufacturing, R&D, human resources and sales.
  
  NewcoGen (http://www.newcogen.com/) was formed in late 1999 to focus on creating and developing new ventures in the life science and information technology fields.NewcoGen applies a systematic entrepreneurial process that is used to identify and develop companies capable of achieving leadership positions in attractive target markets.New venture concepts are either generated internally or sourced externally from a network of NewcoGen advisors, academics, entrepreneurs, venture capital referrals or corporate partners.Based in Cambridge, Massachusetts, NewcoGen has assembled a team of more than 75 life sciences and information technology professionals among its core staff and six current start-up ventures.NewcoGen has approximately $62 million in capital from institutional and corporate partners, including Elan Corporation and Applera Corporation.

Page:  1 2